—
Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high blood pressure, high blood cholesterol, cigarette smoking and Type 2 diabetes. Treatment includes beta blockers, calcium channel blockers, cholesterol-lowering drugs and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBS).Get Sample Report @ https://www.wiseguyreports.com/sample-request/740559-acute-coronary-syndrome-pipeline-review-h2-2016
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Acute Coronary Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Coronary Syndrome (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 3, 9 and 1 respectively.Acute Coronary Syndrome.
Acute Coronary Syndrome (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Coronary Syndrome (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Coronary Syndrome (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Coronary Syndrome (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Coronary Syndrome (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Acute Coronary Syndrome Overview 8
Therapeutics Development 9
Pipeline Products for Acute Coronary Syndrome - Overview 9
Acute Coronary Syndrome - Therapeutics under Development by Companies 10
Acute Coronary Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Acute Coronary Syndrome - Products under Development by Companies 14
Acute Coronary Syndrome - Companies Involved in Therapeutics Development 15
advanceCor GmbH 15
Arena Pharmaceuticals, Inc. 16
Ascendia Pharmaceuticals LLC 17
Athera Biotechnologies AB 18
Bayer AG 19
Cardiome Pharma Corp. 20
Cerenis Therapeutics Holding SA 21
CSL Limited 22
Esperion Therapeutics, Inc. 23
HitGen LTD 24
Japan Tobacco Inc. 25
Lee's Pharmaceutical Holdings Limited 26
LipimetiX Development Inc 27
MedImmune LLC 28
Pfizer Inc. 29
The Medicines Company 30
Verseon Corporation 31
Acute Coronary Syndrome - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
4-WF - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
AEM-28 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
AEM-2802 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Biologics for Acute Coronary Syndrome - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
CER-001 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
clopidogrel bisulphate - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
COR-2 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CSL-112 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
dalcetrapib - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MDCO-216 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
MEDI-6012 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PC-mAb - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
PF-06282999 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
PMC-6 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
Access Report @ https://www.wiseguyreports.com/reports/740559-acute-coronary-syndrome-pipeline-review-h2-2016
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com
Release ID: 146595
Google
RSS